Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
What does it do?
Illumina makes the machines that read DNA. Think of it like this: your DNA is a massive instruction manual written in four letters — Illumina builds the devices that can scan and decode that manual quickly and affordably. Hospitals use their machines to find cancer early, drug companies use them to develop new medicines, and researchers use them to understand genetic diseases. Without Illumina, most of the genetic testing you hear about in the news simply wouldn't be possible at the scale it happens today.
Illumina controls roughly 80% of the global DNA sequencing market, making it the backbone of the entire genomics industry — from cancer diagnostics to at-home ancestry tests. As genetic medicine moves from research labs into everyday healthcare, demand for sequencing is expected to grow significantly over the next decade. Investors care right now because the company is navigating a costly strategic misstep with its Grail acquisition while trying to prove its core business can return to growth.
How does it make money?
Illumina makes most of its money through a 'razor and blades' model — it sells the sequencing machines (the razors) and then earns recurring revenue selling the consumables like reagents and flow cells that customers must keep buying to run tests (the blades). Consumables make up the largest portion of revenue and are the most profitable part of the business. In its latest fiscal year, Illumina brought in $4.3 billion in total revenue, down slightly from $4.4 billion the prior year. A smaller but growing portion of revenue comes from selling sequencing services directly to researchers and clinicians.
Why do investors care?
The long-term bull case is simple: the cost of sequencing a human genome has dropped from $100 million in 2001 to under $200 today, almost entirely thanks to Illumina's technology, and cheaper sequencing means more use cases and more demand. Investors are betting that genomic medicine will become a standard part of healthcare — routine cancer screening, personalized drug prescriptions, newborn genetic testing — and that Illumina sits at the center of all of it. For this story to play out, Illumina needs to reignite revenue growth, fend off rising competition from Chinese rival BGI and its subsidiary MGI, and successfully launch its next-generation sequencing platform. The company also needs to fully put its messy forced divestiture of cancer-detection company Grail behind it.
Deep Dive
MemberA full investor briefing on Illumina, Inc. — history, leadership, risks, and outlook.